Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

Science 333 (6045): 1030-1034

Copyright © 2011 by the American Association for the Advancement of Science

Inhibitory Fc{gamma} Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

Fubin Li, and Jeffrey V. Ravetch*

Abstract: CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, is expressed on antigen-presenting cells (APCs) and is essential for immune activation. Although agonistic CD40 antibodies have been developed for immunotherapy, their clinical efficacy has been limited. We have found that coengagement of the Fc domain of agonistic CD40 monoclonal antibodies (mAbs) with the inhibitory Fc{gamma} receptor Fc{gamma}RIIB is required for immune activation. Direct comparison of mAbs to CD40 enhanced for activating Fc{gamma}R binding, hence capable of cytotoxicity, or for inhibitory Fc{gamma}RIIB binding, revealed that enhancing Fc{gamma}RIIB binding conferred immunostimulatory activity and considerably greater anti-tumor responses. This unexpected requirement for Fc{gamma}RIIB in enhancing CD40-mediated immune activation has direct implications for the design of agonistic antibodies to TNFR as therapeutics.

Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065, USA.
* To whom correspondence should be addressed. E-mail: ravetch{at}rockefeller.edu


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Inhibitory Fc{gamma} Receptor Is Required for the Maintenance of Tolerance through Distinct Mechanisms.
F. Li, P. Smith, and J. V. Ravetch (2014)
J. Immunol. 192, 3021-3028
   Abstract »    Full Text »    PDF »
Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial.
F. Chowdhury, P. W. Johnson, M. J. Glennie, and A. P. Williams (2014)
Cancer Immunology 2, 229-240
   Abstract »    Full Text »    PDF »
Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies.
Z. Liu, K. Gunasekaran, W. Wang, V. Razinkov, L. Sekirov, E. Leng, H. Sweet, I. Foltz, M. Howard, A.-M. Rousseau, et al. (2014)
J. Biol. Chem. 289, 3571-3590
   Abstract »    Full Text »    PDF »
Vaccination with a Fusion Protein That Introduces HIV-1 Gag Antigen into a Multitrimer CD40L Construct Results in Enhanced CD8+ T Cell Responses and Protection from Viral Challenge by Vaccinia-Gag.
S. Gupta, J. M. Termini, F. N. Raffa, C.-A. Williams, R. S. Kornbluth, and G. W. Stone (2014)
J. Virol. 88, 1492-1501
   Abstract »    Full Text »    PDF »
Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer.
L. P. Richman and R. H. Vonderheide (2014)
Cancer Immunology 2, 19-26
   Abstract »    Full Text »    PDF »
Antitumor activities of agonistic anti-TNFR antibodies require differential Fc{gamma}RIIB coengagement in vivo.
F. Li and J. V. Ravetch (2013)
PNAS 110, 19501-19506
   Abstract »    Full Text »    PDF »
Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27-Transgenic Mice.
L.-Z. He, N. Prostak, L. J. Thomas, L. Vitale, J. Weidlick, A. Crocker, C. D. Pilsmaker, S. M. Round, A. Tutt, M. J. Glennie, et al. (2013)
J. Immunol. 191, 4174-4183
   Abstract »    Full Text »    PDF »
Immunotherapy Targeting Inhibitory Fc{gamma} Receptor IIB (CD32b) in the Mouse Is Limited by Monoclonal Antibody Consumption and Receptor Internalization.
E. L. Williams, A. L. Tutt, S. A. Beers, R. R. French, C. H. T. Chan, K. L. Cox, A. Roghanian, C. A. Penfold, C. L. Butts, P. Boross, et al. (2013)
J. Immunol. 191, 4130-4140
   Abstract »    Full Text »    PDF »
Effects of CD40 ligation combined with chemotherapy drugs on human breast cancer cell lines.
Z.-Q. Wang, J. Wang, W.-H. Ling, X.-G. Zhang, and Q. Shi (2013)
Journal of International Medical Research 41, 1495-1504
   Abstract »    Full Text »    PDF »
Engineered antibody Fc variant with selectively enhanced Fc{gamma}RIIb binding over both Fc{gamma}RIIaR131 and Fc{gamma}RIIaH131.
F. Mimoto, H. Katada, S. Kadono, T. Igawa, T. Kuramochi, M. Muraoka, Y. Wada, K. Haraya, T. Miyazaki, and K. Hattori (2013)
Protein Eng. Des. Sel. 26, 589-598
   Abstract »    Full Text »    PDF »
Fc{gamma} receptors enable anticancer action of proapoptotic and immune-modulatory antibodies.
J. M. Kim and A. Ashkenazi (2013)
J. Exp. Med. 210, 1647-1651
   Abstract »    Full Text »    PDF »
Making Macrophages Eat Cancer.
M. H. Kershaw and M. J. Smyth (2013)
Science 341, 41-42
   Abstract »    Full Text »    PDF »
Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2-Induced Apoptosis.
J. S. Swers, L. Grinberg, L. Wang, H. Feng, K. Lekstrom, R. Carrasco, Z. Xiao, I. Inigo, C. C. Leow, H. Wu, et al. (2013)
Mol. Cancer Ther. 12, 1235-1244
   Abstract »    Full Text »    PDF »
T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63-Polyubiquitin-Dependent Signals from Endosomes.
I. Martinez-Forero, A. Azpilikueta, E. Bolanos-Mateo, E. Nistal-Villan, A. Palazon, A. Teijeira, G. Perez-Chacon, A. Morales-Kastresana, O. Murillo, M. Jure-Kunkel, et al. (2013)
J. Immunol. 190, 6694-6706
   Abstract »    Full Text »    PDF »
Agonistic Anti-CD40 Induces Thyrocyte Proliferation and Promotes Thyroid Autoimmunity by Increasing CD40 Expression on Thyroid Epithelial Cells.
T. Kayes, Y. Fang, S. Yu, E. Downey, S. Wang, and H. Braley-Mullen (2013)
J. Immunol. 190, 3928-3938
   Abstract »    Full Text »    PDF »
Agonistic CD40 Antibodies and Cancer Therapy.
R. H. Vonderheide and M. J. Glennie (2013)
Clin. Cancer Res. 19, 1035-1043
   Abstract »    Full Text »    PDF »
Fc-fusion proteins: new developments and future perspectives.
D. M. Czajkowsky, J. Hu, Z. Shao, and R. J. Pleass (2012)
EMBO Mol Med. 4, 1015-1028
   Abstract »    Full Text »    PDF »
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc{gamma} receptor engagement.
F. Li and J. V. Ravetch (2012)
PNAS 109, 10966-10971
   Abstract »    Full Text »    PDF »
Properties of mouse and human IgG receptors and their contribution to disease models.
P. Bruhns (2012)
Blood 119, 5640-5649
   Abstract »    Full Text »    PDF »
Mouse model recapitulating human Fc{gamma} receptor structural and functional diversity.
P. Smith, D. J. DiLillo, S. Bournazos, F. Li, and J. V. Ravetch (2012)
PNAS 109, 6181-6186
   Abstract »    Full Text »    PDF »
The Adjuvant Effects of Antibodies.
M. J. Smyth and M. H. Kershaw (2011)
Science 333, 944-945
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882